Hypersensitivity pneumonitis associated with the use of temozolomide

European Respiratory Journal

Volumn 33, Issue 4, 2009, Pages 931-934

  Koschel, D ^a   Handzhiev, S ^a   Leucht, V ^a   Holotiuk, O ^b   Fisseler Eckhoff, A ^d   Hoffken G ^a,c  

^a Fachkrankenhaus Coswig   (Germany)

^b Gemeinschaftspraxis für Pathologie ^*  (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d HSK Wiesbaden   (Germany)

Author keywords

Drug induced lung disease; Hypersensitivity pneumonitis; Temozolomide

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; PREDNISOLONE; TEMOZOLOMIDE;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; BLOOD GAS ANALYSIS; BRONCHOSCOPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLOW CYTOMETRY; GLIOSARCOMA; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOXIA; LABORATORY TEST; LOW DRUG DOSE; LUNG ALVEOLITIS; LUNG AUSCULTATION; LUNG BIOPSY; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG LAVAGE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; THROMBOSIS;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOPSY; BRONCHOSCOPY; DACARBAZINE; FEMALE; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; PREDNISOLONE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 63849221469     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00004808     Document Type: Article

References (23)

1. Ohgaki H, Biernat W, Reis R, Hegi M, Kleihues P. Gliosarcoma. In: Kleihues P, Cavenee WK, eds. Pathology and Genetic of Tumors of the Nervous System. 2nd Edn. Lyon, IARC Press, 2000; pp. 42-44.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Krown SE, Niedzwiecki D, Hwu WJ, et al. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 2006; 107: 1883-1890.
4. Chang SM, Seiferheld W, Curran W, et al. Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. Int J Radiat Oncol Biol Phys 2004; 59: 1122-1126.
5. Herrlinger U, Rieger J, Koch D, et al. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in neawly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006; 24: 4412-4417.
6. Massin F, Fur A, Reybet-Degat O, Camus P, Jeannin L. [Busulfan-induced pneumopathy]. Rev Mal Respir 1987; 4:3-10.
7. Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 2004; 25: 53-64.
8. Gerard B, Aamdal S, Lee SM, et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur J Cancer 1993; 29A: 711-719.
9. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide versus procarbazine in patients with glio- blastoma multiforme at first relapse. Br J Cancer 2000; 83:588-593.
10. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for reccurent glioblastoma: phase II study from groppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006; 95: 1155-1160.
11. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lympho- penia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22:610-616.
12. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neuro Oncol 2001; 53: 259-263.
13. Chinot O, Barrie M, Cournede A, et al. Phase II study of temozolomide (TMZ) administered on a 7 days on-7 days off regimen as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol 2005; 23: Suppl. 16, 1523.
14. De Sio L, Milano GM, Castellano A, et al. Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer 2006; 47: 30-36.
15. Maldonado F, Limper AH, Lim KG, Aubrey MC. Temozolomide-associated organizing pneumonitis. Mayo Clin Proc 2007; 82: 771-773.
16. Camus P, Foucher P, Bonniaud P, Ask K. Drug-induced infiltrative lung disease. Eur Respir J 2001; 18: Suppl. 32, 93s-100s.
17. Sennekamp HJ. Drug-induced extrinsic allergic alveolitis. In: Sennekamp HJ, ed. Extrinsic Allergic Alveolitis/ Hypersensitivity Pneumonitis. 1st Edn. Munchen/ Orlando, Dustri Verlag 2004; pp. 312-313.
18. Camus P, Martin WJ, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clin Chest Med 2004; 25: 65-75.
19. Morera J, Vidal R, Morell F, Ruiz J, Bernado LL, Laporte JR. Pulmonary fibrosis and amiodarone. Br Med J (Clin Res Ed) 1982; 285: 895.
20. Costabel U, Uzalan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004; 25: 25-35.
21. Shaib FH, Patel B. A case of eosinophilic pleural effusion secondary to valproic acid. Chest 2000; 118: 308S.
22. Sleiman C, Raffy O, Roue C, et al. Fatal pulmonary hemorrhage during high-dose valproate monotherapy. Chest 2000; 117: 613.
23. Pneumotox® Website, 1997. www.pneumotox.com Date last updated: August 2007. Date last accessed: April 2008.